The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Zealand Pharma achieved notable organizational growth in 2024 with a 30% increase in the number of employees compared to 2023 ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

We recently compiled a list of the 12 Best Get Rich Fast Stocks To Buy Now. In this article, we are going to take a look at ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of February 24th, IPO Scoop reports. The company will be issuing 4,500,000 shares at ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Medics in the UK have become the first in the world to successfully administer a pioneering gene therapy that preserves sight ...

While recruitment and regulation are improving, they remain pain points, say speakers at Arena International’s OCT West Coast ...